P. Guruswamy overseeing end-to-end operations at the manufacturing unit since 2017. With over four decades of experience in pharmaceutical manufacturing, he brings deep expertise in plant setup, technical operations, and process excellence across dosage forms including oral liquids, sterile ointments, powders, creams, tablets, and drops. <br/><br/>A postgraduate in Pharmacy (M.Pharm – Pharmaceutics), Mr. Guruswamy began his industry career in 1981 and has since held leadership roles across renowned pharmaceutical organizations. In his earlier role at Strides Pharma Science, he served as Executive Vice President and Plant Head at KRSG until 2011. His work has been instrumental in building and operationalizing over 10 manufacturing facilities with capacities scaling up to 5 billion units. <br/><br/>Known for his strong command over quality, productivity, and technical problem-solving, Mr. Guruswamy has consistently enabled high-performance manufacturing environments and contributed to global client partnerships through his deep technical acumen and execution capability.

Swamy K N leads all technical, analytical, and quality control functions across the group, ensuring the highest standards of scientific rigor, regulatory compliance, and operational excellence. <br/><br/>His key priorities include accelerating the development and commercialization of complex generics, injectables, and specialty products through robust analytical strategies and real-time quality insights. Swamy drives scientific excellence, digital transformation, and global harmonization of QC practices, strengthening laboratory infrastructure and ensuring regulatory readiness across all sites.<br/><br/> Under his leadership, the group has integrated advanced digital platforms such as LIMS, ELN, and automated data review systems, delivering significant gains in compliance and productivity. He has successfully established a global Centre of Excellence for analytical and QC operations and played a pivotal role in major regulatory submissions through advanced characterization strategies. His focus on risk-based quality systems and proactive error reduction frameworks has positioned the organization among industry leaders in quality performance.

Pandurang is responsible for shaping and executing the Quality and Compliance function, ensuring that every product meets the highest global standards for safety, efficacy, and current regulatory requirements. With a strong commitment to excellence and a forward-thinking approach, he plays a key role in driving operational efficiency, simplification, fostering innovation, and supporting the company’s growth in highly regulated global markets.<br/><br/> His key priorities include strengthening InstaPill’s industry leadership by enhancing product quality, accelerating time-to-market, embedding a culture of continuous improvement, and optimizing end-to-end quality systems. Pandurang spearheads digital transformation initiatives that streamline compliance workflows, embedding a culture of continuous improvement, ensure data integrity, and strengthen GMP readiness across the organization. <br/><br/>With over two decades of pharmaceutical industry experience, Pandurang has led successful product launches across multiple dosage forms, secured critical regulatory approvals from various key regulatory agencies across globe, and driven strategic partnerships that contribute to the company’s sustained growth. Known for his sharp attention to detail and decisive leadership, he brings deep expertise in pharmaceutical quality systems, regulatory affairs, and operational excellence, making him a key pillar of InstaPill’s leadership team.

Kalpesh Vohra is a seasoned HR leader with over two decades of experience across human capital consulting and enterprise HR leadership. He leads the company’s people strategy, shaping the design and deployment of integrated human capital programs. He also leads the HR Centre of Excellence across various group entities promoted by the founders, where he oversees the delivery of HR CoE solutions across organization design, talent management, performance and total rewards, HR shared services, and HR digitization. <br/><br/>He has operated at the intersection of business strategy and human capital. Prior to his enterprise leadership roles, he spent a decade at Mercer, leading national practices and industry clusters across Life Sciences, Healthcare, Chemicals, and Industrials. <br/><br/>Throughout his consulting and corporate career, Kalpesh has partnered with top leadership teams to align HR strategy—including organization design, talent management, performance, rewards, and HR transformation—with broader business goals, particularly during greenfield ventures, global expansions, M&A integrations, and enterprise-wide transformations. A trusted advisor and builder of high-impact HR ecosystems, Kalpesh combines consulting precision, operational agility, and a commercial, data-driven approach to strategic people decisions.

Sangeetha K leads the development and execution of regulatory strategies across product development and lifecycle management for the group, with a focus on global regulatory intelligence, compliance, and change management. <br/><br/>Her key priorities include accelerating product approvals, enabling seamless market launches, and providing end-to-end regulatory support—from concept through to approval for specialty products and complex injectables. Sangeetha brings over two decades of experience in leading Regulatory Affairs teams across group companies, having successfully secured approvals for a wide range of product categories in major global markets including the US, EU, UK, Australia, and Canada. <br/><br/>She is recognized for optimizing regulatory pathways, building high-performing teams, and contributing to innovation-driven regulatory frameworks. Notably, she plays a strategic role in enabling the regulatory readiness and compliance for InstaPill, a flagship initiative of the group.

Balaji Sathurappan leads the Formulation Development and Technology Transfer function, with a core mandate to strengthen the R&D pipeline, advance the InstaPill platform, and deliver innovation-led CDMO growth. He drives the identification and development of novel products that address unmet medical needs, enhance product stability, and improve patient acceptability. <br/><br/>His key priorities include optimizing formulation design, ensuring regulatory compliance, reducing product costs through process efficiency, and generating intellectual property. Balaji also collaborates cross-functionally with commercial, production, and quality teams to align scientific development with market requirements.<br/><br/> With several significant contributions to his credit, Balaji has secured product approvals for more than six InstaPill products across global markets and successfully developed the platform’s first small peptide molecule. He has led the establishment of a wide dose range (0.06 mg to 200 mg), completed BE studies for over ten products, and pioneered taste-masking solutions for complex molecules. His work has resulted in multiple patent filings and operational cost efficiencies, making him a key driver of innovation at Tenshi Kaizen.

Keith Dodson leads sales and strategic customer development across North America and UK. He is responsible for expanding the reach of the InstaPill™ technology platform across innovator, generic, and over-the-counter markets, with a focus on enhancing patient access and experience through lyophilized ODT formulations. <br/><br/>With over 30 years of experience in sales and business development, Keith brings a dual perspective from both branded pharmaceutical companies and CDMO service providers. His background includes leadership roles at Catalent, ThermoFisher, Cambrex, Porton, and 3M, where he played pivotal roles in product commercialization across various healthcare segments.<br/><br/>Keith holds an engineering degree and an MBA from the University of Chicago Booth School of Business. His unique blend of technical insight and commercial acumen enables him to craft customized solutions that bring client products to market efficiently and successfully.

Kamal Preet leads the Product Licensing and CDMO business for the EU, APAC and other global regions, focusing on the commercial growth of the InstaPill® technology platform. With a unique ability to bridge technical innovation and commercial strategy, she works closely with clients and internal teams to co-create differentiated drug delivery solutions, particularly for pediatric and geriatric populations.<br/><br/> With over 18 years of experience in pharmaceutical and biopharmaceutical industries, Kamal brings deep expertise across formulation development, commercial negotiations, CDMO partnerships, and global business development. Before joining Tenshi, she played a key role in transforming Stelis Biopharma from a startup into a globally recognized CDMO and held leadership roles at BioCina, Strides, Torrent, and Hospira. <br/><br/>Kamal has consistently built robust pipelines across modalities—including biologics, injectables, oral technologies, and novel platforms such as InstaPill® and SMEDS. She holds an MBA in Pharmaceutical Marketing from NIPER and is known for cultivating trusted client relationships, leading successful commercial programs, and delivering impactful results across markets.